Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007
Executive Summary
Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil